Cancer · 2020 · 77 citations · 17 references
MedicineGeriatric MedicineHematologyAgingHematologic OncologyStem Cell TransplantationAutologous Stem Cell TransplantationHematopoietic Stem Cell TransplantationMultiple MyelomaTransplant OutcomesMultiple Myeloma TherapyMultiple Myeloma TreatmentOverall MortalityRelapsed Multiple MyelomaSurvival After Autologous TransplantationTransplantation For Hematologic MalignanciesTransplantation Outcome Assessment
Background Upfront autologous hematopoietic stem cell transplantation (AHCT) remains an important therapy in the management of patients with multiple myeloma (MM), a disease of older adults. Methods The authors investigated the outcomes of AHCT in patients with MM who were aged ≥70 years. The Center for International Blood and Marrow Transplant Research (CIBMTR) database registered 15,999 patients with MM in the United States within 12 months of diagnosis during 2013 through 2017; a total of 2092 patients were aged ≥70 years. Nonrecurrence mortality (NRM), disease recurrence and/or progression (relapse; REL), progression‐free survival (PFS), and overall survival (OS) were modeled using Cox proportional hazards models with age at transplantation as the main effect. Because of the large sample size, a P value <.01 was considered to be statistically significant a priori. Results An increase in AHCT was noted in 2017 (28%) compared with 2013 (15%) among patients aged ≥70 years. Although approximately 82% of patients received melphalan (Mel) at a dose of 200 mg/m 2 overall, 58% of the patients aged ≥70 years received Mel at a dose of 140 mg/m 2 . On multivariate analysis, patients aged ≥70 years demonstrated no difference with regard to NRM (hazard ratio [HR] 1.3; 99% confidence interval [99% CI], 1‐1.7 [ P = .06]), REL (HR, 1.03; 99% CI, 0.9‐1.1 [ P = 0.6]), PFS (HR, 1.06; 99% CI, 1‐1.2 [ P = 0.2]), and OS (HR, 1.2; 99% CI, 1‐1.4 [ P = .02]) compared with the reference group (those aged 60‐69 years). In patients aged ≥70 years, Mel administered at a dose of 140 mg/m 2 was found to be associated with worse outcomes compared with Mel administered at a dose of 200 mg/m 2 , including day 100 NRM (1% [95% CI, 1%‐2%] vs 0% [95% CI, 0%‐1%]; P = .003]), 2‐year PFS (64% [95% CI, 60%‐67%] vs 69% [95% CI, 66%‐73%]; P = .003), and 2‐year OS (85% [95% CI, 82%‐87%] vs 89% [95% CI, 86%‐91%]; P = .01]), likely representing frailty. Conclusions The results of the current study demonstrated that AHCT remains an effective consolidation therapy among patients with MM across all age groups.
17
SEER Cancer Statistics Review, 1975-2003
Lynn A. G. Ries, D. Harkins, Martin Krapcho et al. · ScholarWorks - Georgia State University (Georgia State University) · 2006 · 11.5K citations · Full text
Medicine, Biostatistics, Oncology +12
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Michel Attal, Valérie Lauwers‐Cancès, Cyrille Hulin et al. · New England Journal of Medicine · 2017 · 1.2K citations · Full text
Medicine, Oncology, Pharmacotherapy +17
Autologous Transplantation and Maintenance Therapy in Multiple Myeloma
Antonio Palumbo, Federica Cavallo, Francesca Gay et al. · New England Journal of Medicine · 2014 · 781 citations · Full text
Medicine, Oncology, Pharmacotherapy +14
Francesca Gay, Stefania Oliva, Maria Teresa Petrucci et al. · The Lancet Oncology · 2015 · 313 citations · Full text
Medicine, Oncology, Pharmacotherapy +17
Luciano J. Costa, Ilene Brill, James Omel et al. · Blood Advances · 2017 · 292 citations · Full text
Medicine, Hematology, Oncology +13